Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)

NCT01696695 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01696695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01696695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2014
Enrollment
882 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer